Centre Forms High-Level Panel to Crack Down on Unethical Pharma Marketing
The Indian government has set up a high-level committee to tackle unethical pharma marketing practices and review the UCPMP framework.
In a significant move to ensure transparency and ethics in the healthcare sector, the Central Government has constituted a specialized committee to examine the regulatory framework governing pharma marketing practices. The panel is tasked with reviewing how pharmaceutical companies interact with healthcare professionals to prevent any improper influence on patient treatment.
Who is Leading the Committee?
The Department of Pharmaceuticals, operating under the Ministry of Chemicals and Fertilizers, has appointed a three-member expert panel to spearhead this initiative. The committee consists of:
- Dr. M. Sirinivas, Member of NITI Aayog (Heading the committee)
- Preeti Sudan, Former Union Health Secretary
- Dr. Naresh Trehan, CMD of Medanta Hospitals
Timeline and Mandate
According to the official order dated October 22, 2026, the committee is required to submit its final recommendations to the Department of Pharmaceuticals within two months of its first meeting. While the first meeting date is currently undecided, the panel will undergo a rigorous consultative process, weighing suggestions and evidence before finalizing its report.
The Fight Against Unethical Influence
The primary goal of this move is to curb unethical marketing. The government wants to ensure that the promotion of medicines remains accurate, balanced, and based on scientific evidence. Crucially, the committee aims to ensure that a doctor's decision to prescribe a particular drug is not swayed by financial inducements, gifts, or other benefits offered by pharma companies.
Evolution of the UCPMP
The government has previously attempted to regulate this space through the Uniform Code for Pharmaceutical Marketing Practices (UCPMP):
- UCPMP 2015: Introduced as a voluntary, industry-led self-regulatory mechanism to promote ethical interactions.
- UCPMP 2024: A strengthened version that superseded the 2015 code to improve implementation architecture and is currently the operative guideline.
Key Objectives of the New Panel
The committee has been given a comprehensive "Terms of Reference" to ensure no loophole is left unplugged. Its core responsibilities include:
- Holistic Examination: Conducting a deep dive into all issues surrounding unethical pharmaceutical marketing.
- Evaluating Efficacy: Testing whether existing monitoring and enforcement mechanisms are actually working.
- Increasing Accountability: Identifying specific measures to ensure greater transparency and effective compliance across the industry.
- Legal Frameworks: Suggesting whether new statutory or legal measures are necessary to strengthen the current regulatory framework.
- Stakeholder Engagement: Consulting with technical experts, professional bodies, and domain specialists to ensure an objective recommendation.
To support these efforts, the Department of Pharmaceuticals will provide the necessary secretarial assistance to the committee as it works toward cleaning up the pharmaceutical marketing landscape in India.